Prof. Emad Abdelhay - Dyslipidemia ESC Guidelines

Introduction to Dyslipidemia Guidelines

Overview of the Discussion

• The speaker expresses gratitude towards Dr. Ahmed Taj and Dr. Ihab Salem for their contributions, indicating a collaborative effort in discussing dyslipidemia guidelines.

• Acknowledgment of the importance of statins in clinical practice, highlighting recent updates from the European Society of Cardiology (ESC) conference held on August 30th in Madrid.

Key Updates on Statin Guidelines

• The speaker aims to simplify the new information regarding statins and changes from previous guidelines, emphasizing a friendly atmosphere reminiscent of Ismailia's hospitality.

• An agenda is set to cover total cardiovascular risk estimation and non-statin therapies as part of the discussion.

Cardiovascular Risk Estimation

Understanding Risk Assessment Tools

• Introduction to a mobile application used for estimating cardiovascular risk, known as SCORE (Systematic Coronary Risk Evaluation). This tool is crucial for assessing patients aged 40 to 69 years old.

• Differentiation between two types of SCORE: standard SCORE for general assessment and SCORE2 for older patients aged 70 to 89 years old. Specific exclusions are noted for certain high-risk conditions such as established coronary artery disease or chronic kidney disease (CKD).

High-Risk Patient Identification

• Five specific patient categories are excluded from using the standard SCORE due to their high-risk status:

• Patients with established coronary artery disease.

• Those with chronic kidney disease.

• Diabetic patients.

• Individuals with familial hypercholesterolemia.

• Patients presenting with LDL levels above 190 mg/dL.

Importance of High-Sensitivity C-Reactive Protein

New Biomarkers in Clinical Practice

• Discussion on incorporating high-sensitivity C-reactive protein (hsCRP) testing into routine assessments, which can indicate inflammatory processes within patients at risk for cardiovascular events. The cost-effectiveness of this test is highlighted as well.

Non-Statin Therapies

Introduction to Non-Statin Options

• Focus shifts towards non-statin therapies like bempedoic acid, which reduces LDL cholesterol through different mechanisms than statins, specifically targeting upstream enzymes without affecting muscle tissue significantly. This minimizes side effects associated with traditional statin therapy.

Dosage and Efficacy

• Bempedoic acid has shown efficacy in lowering LDL cholesterol by approximately 23% when used alone; combined use with statins or ezetimibe can enhance this reduction further by up to 38%. Careful monitoring is advised due to potential side effects like tendon inflammation or hyperglycemia associated with its use.

Advanced Therapeutics

Emerging Treatments

• Introduction of newer agents such as inclisiran, an RNA interference therapy that targets PCSK9 pathways, showing promise particularly in familial hypercholesterolemia cases where traditional treatments have failed or are insufficiently effective. This treatment requires careful administration due to its injection-based delivery method but offers significant triglyceride reduction benefits over time when properly utilized in clinical settings.

LDL vs Non-HDL Cholesterol Management

Distinguishing Lipid Profiles

• Emphasis on understanding both LDL cholesterol and non-HDL cholesterol metrics during patient evaluations; recognizing that non-HDL includes all atherogenic lipoproteins provides a more comprehensive view of cardiovascular risk management strategies tailored toward individual patient profiles based on their unique lipid presentations and overall health status.

Primary Prevention Strategies

Recommendations for At-Risk Populations

• New guidelines suggest aggressive management strategies even among primary prevention populations who have not yet experienced cardiovascular events but present elevated risk scores; targets include reducing LDL levels below specific thresholds based on individual risk categorizations (e.g., <55 mg/dL for very high-risk individuals). Attention is drawn towards ensuring these recommendations are effectively communicated within clinical practices moving forward so that they can be implemented successfully across diverse patient demographics while maintaining safety protocols throughout treatment regimens discussed earlier in the session.

This structured approach ensures clarity while providing essential insights into dyslipidemia management according to updated guidelines discussed during the presentation.